COMPARATIVE ANALYSIS OF THE CONTENT IN LYMPH OF HORMONES DRAWING IN PATHOGENESIS OF BREAST CANCER IN RATS WISTAR

The aim of the research was to study the levels of hormones involved in the pathogenesis of BC in the lymph of the thoracic duct. Methods. BC induced by the introduction of n-methyl-N-nitrosourea rats of Wistar breed. The animals underwent only surgery chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil). In some animals combined surgery followed by a course of chemotherapy, and in some animals advanced therapy fragmented DNA. In the lymph examined the contents of the follicle-stimulating hormone (FSH), prolactin, luteinizing hormone (LH), estradiol (E2 ) and thyroglobulin (TG). Results. It is shown that surgical removal of tumors in the mammary gland leads to lower levels in the lymph LH and E2 . The combination of surgery with a course of chemotherapy leads to lower levels in the lymph FSH. Chemotherapy without surgical removal of tumors in the mammary gland leads to a decrease in the concentration of E2 in the lymph. Conclusion. The concentration of sex hormones and thyroglobulin in the lymph of the thoracic duct in breast cancer in rats depends on the type of treatment.

breast cancer, neoadjuvant polychemotherapy, sex hormones, thyroglobulin, lymph

1. Besednova N.N., Fedyanina L.N. Anticancer effect of exogenous deoxyribonucleic acid // Tihookeanskij medicinskij zhurnal. 2009. № 3. P. 12–18. [in Russian]

2. Stenina M.B., Frolova M.A. Breast cancer: the most important scientific events and the conclusions of the last years // Prakticheskaja onkologija. 2011. № 1. P. 6–11. [in Russian]

3. Bernichtein S., Touraine P., Goffin V. New concepts in prolactin biology // J. Endocrinology. 2010. Vol. 206 (1). P. 1–11. doi: 10.1677/JOE-10-0069.

4. Clemons M., Goss P. Estrogen and the risk of breast cancer // N. Engl. J. Med. 2001. Vol. 344 (4). P. 276–285.

5. Farhat G.N., Cummings S.R., Chlebowski R.T., Parimi N., Cauley J.A., Rohan T.E., Huang A.J., Vitolins M., Hubbell F.A., Manson J.E., Cochrane B.B., Lane D.S., Lee J.S. Sex hormone levels and risks of estrogen receptor–negative and estrogen receptor–positive breast cancers // J. Natl. Cancer Inst. 2011. Vol. 103 (7). P. 562–570. doi: 10.1093/jnci/djr031.

6. Figueiredo H.F., Ulrich-Lai Y.M., Choi D.C., Herman J.P. Estrogen potentiates adrenocortical responses to stress in female rats // Am. J. Physiol. Endocrinol. Metab. 2007. Vol. 292 (4). P. 1173–1182.

7. Nitze L.M., Galsgaard E.D., Din N., Lund V.L., Rasmussen B.B., Berchtold M.W., Christensen L., Panina S. Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer // Breast Cancer Res. Treat. 2013. Vol. 142 (1). P. 31–44. doi: 10.1007/s10549013-2731-7.

8. Rose D.P., Davis T.E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients // Cancer Res. 1980. Vol. 40 (11). P. 4043–4047.

9. Suba Z. Circulatory estrogen level protects against breast cancer in obese women // Recent. Pat. AntiCancer Drug Discov. 2013. Vol. 8 (2). P. 154–167.

10. Szychta P., Szychta W., Gesing A., Lewiński A., KarbownikLewińska M. TSH receptor antibodies have predictive value for breast cancer – retrospective analysis // Thyroid Research. 2013. Vol. 6 (1). P. 8–15. doi: 10.1186/1756-6614-6-8.

11. Zhou J., Chen Y., Huang Y., Long J., Wan F., Zhang S. Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer // Oncology letters. 2013. Vol. 6 (4). P. 1128–1132.